What To Expect When Eli Lilly Reports Q4 Earnings On Thursday?
Eli Lilly And Co (NYSE:LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on February 6 ...
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...
Nasdaq3d
With Zepbound Not Matching Expectations, Should Investors Give Up on Eli Lilly?
cancer drug Verzenio, and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes ...
FiercePharma5d
Novartis' Kisqali off to 'very rapid' launch in early breast cancer, CEO says. Can it keep up the momentum?
One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...
Nasdaq5d
Eli Lilly Unusual Options Activity
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity ...
Aristotle Atlantic Focus Growth Strategy Increased its Holdings in Eli Lilly and Company (LLY)
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Focus Growth Strategy” fourth quarter 2024 investor ...
Got $1,000? 2 Top Growth Stocks to Buy Right Now
If you are looking to invest in top growth stocks, these companies can experience more volatility than the average stock.